PVCT Stock Overview
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Provectus Biopharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.20 |
52 Week High | US$0.22 |
52 Week Low | US$0.056 |
Beta | 0.63 |
1 Month Change | 38.68% |
3 Month Change | 97.20% |
1 Year Change | 17.96% |
3 Year Change | 181.03% |
5 Year Change | 268.22% |
Change since IPO | -82.09% |
Recent News & Updates
Recent updates
Shareholder Returns
PVCT | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -0.3% | -0.2% | 0.6% |
1Y | 18.0% | 23.9% | 29.5% |
Return vs Industry: PVCT underperformed the US Pharmaceuticals industry which returned 23.1% over the past year.
Return vs Market: PVCT underperformed the US Market which returned 29.8% over the past year.
Price Volatility
PVCT volatility | |
---|---|
PVCT Average Weekly Movement | 12.2% |
Pharmaceuticals Industry Average Movement | 9.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PVCT's share price has been volatile over the past 3 months.
Volatility Over Time: PVCT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 4 | n/a | https://www.provectusbio.com |
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. The company’s lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis; and PV-305 for the treatment of infectious keratitis.
Provectus Biopharmaceuticals, Inc. Fundamentals Summary
PVCT fundamental statistics | |
---|---|
Market cap | US$83.90m |
Earnings (TTM) | -US$3.17m |
Revenue (TTM) | US$601.44k |
137.4x
P/S Ratio-26.1x
P/E RatioIs PVCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PVCT income statement (TTM) | |
---|---|
Revenue | US$601.44k |
Cost of Revenue | US$1.61m |
Gross Profit | -US$1.00m |
Other Expenses | US$2.17m |
Earnings | -US$3.17m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0076 |
Gross Margin | -166.91% |
Net Profit Margin | -527.24% |
Debt/Equity Ratio | -40.8% |
How did PVCT perform over the long term?
See historical performance and comparison